Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial

Guillermo Garcia-Manero, Pierre Fenaux, Aref Al-Kali, Maria R. Baer, Mikkael A. Sekeres, Gail J. Roboz, Gianluca Gaidano, Bart L. Scott, Peter Greenberg, Uwe Platzbecker, David P. Steensma, Suman Kambhampati, Karl Anton Kreuzer, Lucy A. Godley, Ehab Atallah, Robert Collins, Hagop Kantarjian, Elias Jabbour, Francois E. Wilhelm, Nozar AzarniaLewis R. Silverman

Research output: Contribution to journalArticlepeer-review

88 Scopus citations

Fingerprint Dive into the research topics of 'Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial'. Together they form a unique fingerprint.

Medicine & Life Sciences